Healthcare reform in the United States and China: pharmaceutical market implications

Table 4 Prescription drug expenditures in china by treatment site (US$, billions, nominal)

	General hospitals		Specialized hospitals		CHCs		THCs		TCM		Total Rx
	Inpatient	Outpatient	Inpatient	Outpatient	Inpatient	Outpatient	Inpatient	Outpatient	Inpatient	Outpatient
2011	38.2	22.8	4.6	2.8	0.4	3.5	2.6	3.3	0.6	1.0	79.9
2012	46.8	26.8	5.9	3.5	0.5	4.2	2.6	3.3	0.8	1.2	95.4
2015	81.8	41.2	11.4	6.1	0.8	6.6	2.4	2.9	1.4	2.1	156.8
2020	148.7	61.9	24.3	11.4	1.5	10.8	1.5	1.7	3.5	4.4	269.6

Notes: Figures initially calculated in RMB (Renminbi), converted to US$ using actual rates through 2013 and projections of $1: RMB 5.8 for 2015 and 1$: 5.5 RMB for 2020. These align to market expectations for exchange rates and policy statements from the People’s Bank of China. Total prescription drug sales for 2011 and 2012 differ from Table 5 due to discrepancies in the original data sources.
Source: People’s Republic of China (2012) Health Statistical Yearbook, Beijing: P.R. China.

ISSN: 2052-3211